GlassScriptPhysician profile
Isabel C Valencia
NPI 1700816162
$4,066.52
in general payments reported to CMS, 2019-2025
23 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.16 · 2022: $174 · 2023: $955 · 2024: $1,298 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,692 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.96 |
| Education | $175.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $897.39 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $421.79 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Novartis Pharmaceuticals Corporation | $371.46 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $326.66 | 2024-2025 | Dupixent, Libtayo |
| Abbvie INC. | $275.70 | 2022-2025 | Skyrizi |
| Galderma Laboratories, L.P. | $254.45 | 2022-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $221.42 | 2024-2025 | Tremfya |
| Amgen INC. | $216.32 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $145.21 | 2023-2024 | Vtama |
| Genzyme Corporation | $123.33 | 2024-2025 | |
| Kerecis Limited | $116.69 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Leo Pharma INC. | $111.13 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $99.50 | 2023-2025 | Ebglyss, Taltz |
| Incyte Corporation | $98.70 | 2022-2025 | Opzelura |
| Almirall LLC | $83.80 | 2023-2024 | Seysara |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $62.93 | 2023-2024 | |
| Mayne Pharma Commercial LLC | $61.94 | 2024 | |
| Organogenesis INC. | $46.64 | 2021-2024 | |
| Organon LLC | $42.88 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $30.41 | 2023-2025 | Sotyktu |
| Botanix Sb INC | $20.72 | 2025 | Sofdra |
| Surgenex LLC | $19.63 | 2025 | Renograft, Surmatrix, Ardeograft |
| Fidia Pharma USA INC. | $17.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Valencia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.